ArticleREC, interventional cardiology2025
Efficacy of ultrasound renal denervation reducing blood pressure: a systematic review and meta-analysis.
Article in REC, interventional cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Renal Denervation in Severe Neurogenic Dysautonomia: The RANSOM Prospective Experience.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and objectives: Ultrasound renal denervation (uRDN) has emerged as an innovative therapeutic approach for the treatment of hypertension. However, its efficacy compared to medication remains uncertain. We aimed to assess the efficacy profile of uRDN vs sham groups focusing on its impact on daytime ambulatory blood pressure, 24-hour blood pressure, home blood pressure and office blood pressure. Methods: We conducted a systematic search across Embase, PubMed, and Cochrane Library databases from their inception up 1 November 2024 to identify randomized controlled trials evaluating the efficacy of uRDN. Statistical analyses were performed using RevMan 6.3 software, utilizing the mean and standard deviation method to calculate mean differences with a 95% confidence interval (95%CI). Results: A total of 4 studies were included in the final analysis with 642 patients. uRDN significantly reduced daytime ambulatory systolic blood pressure (SBP) (-5.12 mmHg; 95%CI, -6.07 to -4.16; P ≤ .00001), 24-h SBP (-4.87 mmHg; 95%CI, -6.53 to -3.21]; P ≤ .00001), office SBP (-5.03 mmHg; 95%CI, -6.27 to -3.79; P ≤ .00001) and showed a decrease in patient medication 6 months after the procedure. Conclusions: Using uRDN leads to a lower blood pressure in patients within 2 months following the procedure. Additionally, after 6 months a significant decrease in drug use is observed.This meta-analysis protocol was registered on PROSPERO on 7 July 2024 (CRD42024562852).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.